
    
      Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with
      minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance,
      or complain of cognitive symptoms, with poor health-related quality of life. This study will
      compare L-ornithine-L-aspartate with placebo for 60 days to assess the effectiveness, safety
      and health-related quality of life of this drug.
    
  